Neuberg Diagnostics Plans $350 Million IPO in 2026 as Healthcare Demand Rises

Chennai, November 11, 2025: Neuberg Diagnostics is preparing for an initial public offering (IPO) worth $350 million in 2026, amid growing investor interest in India’s expanding healthcare sector. The company has initiated discussions with investment bankers to advance the listing process.

Dr. GSK Velu, Founder and Chairman of Neuberg Diagnostics, also indicated plans to pursue subsequent listings of Trivitron Healthcare and Maxivision Eye Hospitals. The final structure and timelines of these proposed IPOs are currently under evaluation.

What Does The Management Say?

Founder and Chairman of the company, Velu, said that the group is profoundly evaluating several options for the company and its sister concerns. He also said that IPO is one potential and efficient way. He affirmed that the best structure for the three firms will be determined by the key stakeholders and advisors in the coming months.

Market Context

On an annual basis, India’s diagnostics market is projected to grow 9.2% to hit $26.7 billion by 2033. This growth is fueled by the rising prevalence of chronic diseases and increased demand for lab testing services. IPOs have garnered an average return of over 15% this year. Even though half of the new listings have traded only below the issue price.

Company Footprint and Recent Funding

Nueberg was founded in 2017, and it spans over 250 Indian cities. It has made its presence in the UAE, the US, and South Africa. The company’s portfolio spread across multiple arenas such as genomics, haemato-oncology, histopathology, wellness programs, and rare-disease management.

In order to bolster personalised medicine, integrated diagnostics capabilities, and to pursue inorganic expansion spanning India, the company has raised approximately ₹940 crore from Kotak Alternate Asset Managers.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations